Stalicla Secures CHF 2 Million Financing from Addex Therapeutics to Advance Precision Medicine for Autism and Neurodevelopmental Disorders
Key Insights
Geneva-based Stalicla SA closed a CHF 2 million financing round led by Addex Therapeutics (search) to sustain operations and advance its precision medicine programs for neurodevelopmental disorders.
The funding supports Stalicla's DEPI precision neuro platform and autism-focused assets STP1 and STP2, while the company prepares for Phase 2 trials targeting specific autism subpopulations.
Stalicla's STP7 (mavoglurant) program, the most clinically advanced mGluR5 (search) negative allosteric modulator, continues toward Phase 3 trials with full NIH-NIDA funding.
Geneva-based clinical-stage biotech company Stalicla SA announced the successful closure of a CHF 2 million financing round led by Addex Therapeutics (search) on June 30, 2025. The funding will sustain operations and program development in neurodevelopmental disorders as the company prepares for its upcoming Series C financing and partnering of key programs.
Precision Medicine Platform Gains Investor Confidence
The financing underscores investor confidence in Stalicla's innovative DEPI precision neuro platform and its portfolio of precision autism assets, STP1 and STP2. The company has established a clinically validated neuro precision development platform that effectively identifies stratified patient subgroups, enabling the advancement of personalized treatment options.
"This financing is a key step in securing our runway to reach a number of important milestones including our Series C financing," said Lynn Durham, CEO of Stalicla. "We are grateful for the support from the Addex-led syndicate, which enables us to continue advancing our precision medicine programs and prepare for transformative clinical trials in autism and substance use disorders."
Clinical Pipeline Advancement
Stalicla is currently preparing to initiate Phase 2 trials for its leading neurodevelopmental disorder asset, STP1, along with a second asset, both targeting specific subpopulations within autism. The company is also progressing its STP7 (mavoglurant) program, described as the most clinically advanced mGluR5 (search) negative allosteric modulator.
The STP7 program reached a significant milestone in October 2024 with the conclusion of a Phase 3 enabling drug-drug interaction study. The Phase 3 development continues to be financed by the National Institute of Health-National Institute on Drug Abuse (NIH-NIDA) under a Collaborative Research and Development Agreement, with full funding provided by the US government.
Leadership Changes and Strategic Partnership
As part of the financing agreement, Tim Dyer has been appointed to the Board of Directors of Stalicla and nominated as Chairman. Dyer, who serves as CEO of Addex Therapeutics (search), expressed confidence in Stalicla's platform and clinical assets.
"Stalicla has built a world leading precision medicine neurodevelopment disorder platform and portfolio of clinical stage assets as well as adding tremendous value to their Phase 3 ready substance use disorders asset, STP7," said Dyer. "We look forward to supporting Lynn Durham and her team as they bring these important medicines to patients."
Company Funding History
Stalicla SA has raised over $50 million to date in equity and more than $30 million in non-dilutive funding to propel its mission to transform the landscape of neurodevelopmental disorder treatments. The Swiss clinical stage biopharmaceutical company continues to focus on developing personalized treatment options for patients with neurodevelopmental and neuropsychiatric disorders.
The partnership with Addex Therapeutics (search), a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders, represents a strategic alignment in the neurological therapeutics space. Addex's lead drug candidate, dipraglurant, is under evaluation for brain injury recovery, including post-stroke and traumatic brain injury recovery.